Dr. Larson on Immunotherapy for Colorectal Cancer

Tim G. Larson, MD, Minnesota Oncology discusses the development of immunotherapy for patients with colorectal cancer (CRC).

Immunotherapies have seen success in patients with microsatellite instability-high (MSI-H) CRC even though this only includes a small percentage of patients, states Larson. Patients with microsatellite stable (MSS) CRC have not seen the same results but this is under current investigation since they make up 95% of the patient population.

Unique combinations or molecules might show some signs of progress for these patients, explains Larson.